Breakthrough drug slashes bleeding risk for hemophilia patients

NCT ID NCT03315455

Completed Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

Summary

This study tested whether a new preventive drug called emicizumab could reduce the number of bleeding episodes in people with hemophilia A. It involved 85 participants, including teens and adults, who were prone to frequent bleeds. They were given either the drug as a weekly or monthly injection or received no preventive treatment, to see which approach worked better.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Peking Union Medical College Hospital

Beijing, 100730, China
Penang General Hospital

George Town, Pulau Pinang, 10990, Malaysia
Prince of Wales Hospital

Shatin, Hong Kong
Queen Elizabeth Hospital

Sabah, Sabah, 88586, Malaysia
Queen Mary Hospital

Hong Kong, Hong Kong
Ramathibodi Hospital

Bangkok, 10400, Thailand
Ruijin Hospital Shanghai Jiaotong University School of Medicine

Shanghai, 200025, China
Southern Medical University Nanfang Hospital

Guangdong Province Guangzhou City, 510515, China
Tianjin Institute of Hematology & Blood Diseases Hospital

Tianjin, 300020, China
Tongji Hosp, Tongji Med. Col, Huazhong Univ. of Sci. & Tech

Wuhan, 430030, China
Xiangya Hospital of Centre-South University

Changsha, 410008, China
Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology

Wuhan, 430022, China

Conditions

Explore the condition pages connected to this study.

HEMOPHILIA A